Cover Image
市場調查報告書

美國的癌症相關的診斷產品市場:超音波、微創切片檢查、細胞篩檢

U.S. Markets for Oncology-Related Diagnostic Ultrasound, Minimally Biopsy, and Tissue Screening Products

出版商 Medtech Insight 商品編碼 297205
出版日期 內容資訊 英文 261 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的癌症相關的診斷產品市場:超音波、微創切片檢查、細胞篩檢 U.S. Markets for Oncology-Related Diagnostic Ultrasound, Minimally Biopsy, and Tissue Screening Products
出版日期: 2014年01月01日 內容資訊: 英文 261 Pages
簡介

在美國癌症是次於心臟病的第2大死因。推算在該國2014年癌症確診患者約170萬人,約58萬5,720人死亡。超音波、微創切片檢查、細胞篩檢診斷設備,讓醫生可最快在可治療階段偵測到腫瘤。2012年的癌症相關超音波、微創切片檢查、細胞篩檢診斷設備的裝置約9,200萬件,從這些治療約產生11億美元的產品銷售額。癌症相關的超音波、微創切片檢查、細胞篩檢診斷設備的銷售額,在預測期間內(2012-2017年)將以3.9%擴大,預計2017年達到14億美元。

本報告提供美國的癌症相關診斷產品(超音波、微創切片檢查、細胞篩檢)市場相關調查、主要的癌症類型臨床、統計資料、各產品區隔的市場分析與競爭趨勢,及參與企業簡介等等,為您概述為以下內容。

摘要整理

第1章 癌症統計的更新

  • 癌症細胞的採集能力
  • 癌症進展包含的基因變化的目錄
  • 癌症的進展相關的風險因素
  • 癌症的癌症分期
  • 新的癌症案例,癌症的得病率,及癌症的死亡
  • 主要的癌症類型臨床、統計資料
    • 腦、其他神經系統癌症
    • 乳癌
    • 大腸癌
    • 腎臟/腎盂癌症
    • 白血病
    • 肺/支氣管癌症
    • 淋巴瘤
    • 黑色素瘤
    • 口腔/咽喉癌
    • 卵巢癌
    • 胰臟癌
    • 前列腺癌
    • 甲狀腺癌
    • 膀胱癌
    • 子宮癌

第2章 美國的癌症相關診斷產品市場:超音波、微創切片檢查、細胞篩檢產品

  • 超音波診斷設備:市場分析
    • 技術
    • 治療數
    • 產品
    • 市場預測
    • 競爭分析
  • 微創切片設備:市場分析
  • 細胞篩檢:市場分析

第3章 企業簡介

  • Analogic Corporation
  • Bard Biopsy Systems/ Bard Peripheral Vascular, Inc./ C.R. Bard, Inc
  • Becton, Dickinson and Company
  • CareFusion Corporation
  • Fujifilm SonoSite, Inc./Fujifilm Medical Systems USA, Inc./ Fujifilm Holdings America Corporation/FUJIFILM
  • GE Healthcare, Inc./General Electric Company
  • Hitachi Aloka Medical America/Hitachi Aloka Medical/日立醫學/日立
  • Hologic, Inc.
  • Mammotome/Devicor Medical Products, Inc.
  • Mindray Medical USA Corporation/Mindray Medical International LTD
  • Philips Healthcare, Inc./Royal Philips NV
  • Qiagen NV
  • Samsung Medison/Samsung Electronics America, Inc./ Samsung Electronics Co., LTD/Samsung
  • Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG
  • Toshiba America Medical Systems, Inc./東芝

附錄:企業清單

目錄
Product Code: A417

Cancer is the second-leading cause of death in the United States (U.S.) after heart disease. It is estimated that nearly 1.7 million people in the country will be diagnosed with cancer in 2014, and that approximately 585,720 will die from the disease. In the fight against cancer, diagnostic ultrasound imaging, minimally invasive biopsy, and tissue screening are among the methods that allow physicians to detect malignancies at their earliest and most treatable stages.

In 2012, approximately 92.0 million oncology-related diagnostic ultrasound, minimally invasive biopsy, and tissue screening procedures were performed in the U.S. Together, these procedures generated approximately $1.1 billion in corresponding product sales; it is expected that during the forecast period covered by this report, sales of diagnostic ultrasound, minimally invasive biopsy, and tissue screening products for oncology-related indications will increase at a compound annual rate of 3.9%, reaching nearly $1.4 billion in the year 2017.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic ultrasound, minimally invasive biopsy, and tissue screening products arena.

Covered topics in this report include an overview of cancer in the U.S. including discussions of the different forms of the disease; automated and semi-automated tissue screening technologies; capacitive micromachined ultrasonic transducers; contrast-enhanced ultrasound; core needle biopsy systems; diagnostic ultrasound systems; Doppler and tissue harmonic imaging; fine-needle aspiration; human papilloma virus testing systems; minimally invasive biopsy; Papanicolaou smear testing systems; photoacoustic imaging; risk factors for cancer development; statistics covering new cancer cases, cancer prevalence, and cancer-related deaths; tissue elastography; and vacuum-assisted biopsy systems; among others

Table of Contents

EXECUTIVE SUMMARY

  • i. New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer
  • ii. Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Procedures
  • iii. Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Products
    • a. Oncology-Related Diagnostic Ultrasound Systems Market Segment
    • b. Minimally Invasive Biopsy Systems Market Segment
    • c. Tissue Screening Systems Market Segment
  • iv. Methodology
  • Exhibit ES-1: Estimated New Cases, Prevalence,and Deaths for Selected Types of Cancer
  • Exhibit ES-2: Oncology-Related Diagnostic Ultrasound,Minimally Invasive Biopsy, and Tissue Screening, Combined Procedure Volumes Forecast, 2012-2017
  • Exhibit ES-3: Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Products, Combined Market Forecast, 2012-2017
  • Exhibit ES-4: Oncology-Related Diagnostic Ultrasound Systems, Market Forecast, 2012-2017
  • Exhibit ES-5: Minimally Invasive Biopsy Products, Market Forecast, 2012-2017
  • Exhibit ES-6: Tissue Screening Products, Market Forecast, 2012-2017

1. CANCER STATISTICS UPDATE

  • 1.1. Acquired Capabilities of Cancer Cells
  • 1.2. Cataloging Genomic Alterations Involved in the Development of Cancer
  • 1.3. Risk Factors Associated with the Development of Cancer
  • 1.4. Cancer Staging
  • 1.5. New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer
  • 1.6. Clinical and Statistical Data for Selected Types of Cancer
    • 1.6.1. Brain and Other Nervous System Cancers
      • 1.6.1.1. Etiology
      • 1.6.1.2. Epidemiology
    • 1.6.2. Breast Cancer
      • 1.6.2.1. Etiology
      • 1.6.2.2. Epidemiology
    • 1.6.3. Colorectal Cancer
      • 1.6.3.1. Etiology
      • 1.6.3.2. Epidemiology
    • 1.6.4. Kidney/Renal Pelvis Cancer
      • 1.6.4.1. Etiology
      • 1.6.4.2. Epidemiology
    • 1.6.5. Leukemia
      • 1.6.5.1. Etiology
      • 1.6.5.2. Epidemiology
    • 1.6.6. Lung/Bronchus Cancer
      • 1.6.6.1. Etiology
      • 1.6.6.2. Epidemiology
    • 1.6.7. Lymphoma
      • 1.6.7.1. Etiology
      • 1.6.7.2. Epidemiology
    • 1.6.8. Melanoma
      • 1.6.8.1. Etiology
      • 1.6.8.2. Epidemiology
    • 1.6.9. Oral Cavity and Pharyngeal Cancers
      • 1.6.9.1. Etiology
      • 1.6.9.2. Epidemiology
    • 1.6.10. Ovarian Cancer
      • 1.6.10.1. Etiology
      • 1.6.10.2. Epidemiology
    • 1.6.11. Pancreatic Cancer
      • 1.6.11.1. Etiology
      • 1.6.11.2. Epidemiology
    • 1.6.12. Prostate Cancer
      • 1.6.12.1. Etiology
      • 1.6.12.2. Epidemiology
    • 1.6.13. Thyroid Cancer
      • 1.6.13.1. Etiology
      • 1.6.13.2. Epidemiology
    • 1.6.14. Urinary Bladder Cancer
      • 1.6.14.1. Etiology
      • 1.6.14.2. Epidemiology
    • 1.6.15. Uterine Cancer
      • 1.6.15.1. Etiology
      • 1.6.15.2. Epidemiology
  • Exhibit 1-1: Estimated New Cases, Prevalence, and Deaths for Selected Types of Cancer
  • Exhibit 1-2: Brain and Other Nervous System Cancers, Facts And Figures
  • Exhibit 1-3: Breast Cancer, Facts And Figures
  • Exhibit 1-4: Colorectal Cancer, Facts And Figures
  • Exhibit 1-5: Kidney/Renal Pelvis Cancers, Facts And Figures
  • Exhibit 1-6: Leukemia, Facts and Figures
  • Exhibit 1-7: Lung/Bronchus Cancer, Facts And Figures
  • Exhibit 1-8: Hodgkin Lymphoma, Facts and Figures
  • Exhibit 1-9: Non-Hodgkin Lymphoma, Facts and Figures
  • Exhibit 1-10: Melanoma of the Skin, Facts and Figures
  • Exhibit 1-11: Oral Cavity and Pharyngeal Cancers, Facts and Figures
  • Exhibit 1-12: Ovarian Cancer, Facts and Figures
  • Exhibit 1-13: Pancreatic Cancer, Fact and Figures
  • Exhibit 1-14: Prostate Cancer, Facts And Figures
  • Exhibit 1-15: Thyroid Cancer, Fact and Figures
  • Exhibit 1-16: Urinary Bladder Cancer, Fact and Figures
  • Exhibit 1-17: Cancer of the Uterine Corpus, Facts and Figures
  • Exhibit 1-18: Cancer of the Uterine Cervix, Facts and Figures

2. U.S. MARKETS FOR ONCOLOGY-RELATED DIAGNOSTIC ULTRASOUND, MINIMALLY INVASIVE BIOPSY, AND TISSUE SCREENING PRODUCTS

  • 2.1. Diagnostic Ultrasound Systems, Market Analysis
    • 2.1.1. Technologies
      • 2.1.1.1. Doppler Imaging
      • 2.1.1.2. Tissue Harmonic Imaging
      • 2.1.1.3. Tissue Elastography
      • 2.1.1.4. Contrast-Enhanced Ultrasound
    • 2.1.2. Procedure Volumes
    • 2.1.3. Products
    • 2.1.4. Market Forecast
    • 2.1.5. Competitive Analysis
  • 2.2. Minimally Invasive Biopsy Systems, Market Analysis
    • 2.2.1. Technologies
      • 2.2.1.1. Core Needle/Fine Needle/Multipurpose Tool-Assisted Biopsy
      • 2.2.1.2. Vacuum-Assisted Biopsy
    • 2.2.2. Procedure Volumes
    • 2.2.3. Products
    • 2.2.4. Market Forecast
    • 2.2.5. Competitive Analysis
  • 2.3. Tissue Screening, Market Analysis
    • 2.3.1. Technologies
    • 2.3.2. Procedure Volumes
    • 2.3.3. Products
    • 2.3.4. Market Forecast
    • 2.3.5. Competitive Analysis
  • Exhibit 2-1: Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening, Combined Procedure Volumes Forecast, 2012-2017
  • Exhibit 2-2: Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Products, Combined Market Forecast, 2012-2017
  • Exhibit 2-3: Oncology-Related Diagnostic Ultrasound, Procedure Volumes Forecast, 2012-2017
  • Exhibit 2-4: 2014, Selected Diagnostic Ultrasound Systems
  • Exhibit 2-5: Oncology-Related Diagnostic Ultrasound Systems, Market Forecast, 2012-2017
  • Exhibit 2-6: 2012, Oncology-Related Diagnostic Ultrasound Systems Market, Share by Supplier
  • Exhibit 2-7: Minimally Invasive Biopsy, Procedure Volumes Forecast, 2012-2017
  • Exhibit 2-8: 2014, Selected Minimally Invasive Biopsy Products
  • Exhibit 2-9: Minimally Invasive Biopsy Products, Market Forecast, 2012-2017
  • Exhibit 2-10: 2012, Minimally Invasive Biopsy Products Market, Share by Supplier
  • Exhibit 2-11: Tissue Screening, Procedure Volumes Forecast, 2012-2017
  • Exhibit 2-12: 2014, Selected Tissue Screening Products
  • Exhibit 2-13: Tissue Screening Products, Market Forecast, 2012-2017
  • Exhibit 2-14: 2012, Tissue Screening Products Market, Share by Supplier

3. COMPANY PROFILES

  • 3.1. Analogic Corporation
  • 3.2. Bard Biopsy Systems/ Bard Peripheral Vascular, Inc./ C.R. Bard, Inc
  • 3.3. Becton, Dickinson and Company
  • 3.4. CareFusion Corporation
  • 3.5. Fujifilm SonoSite, Inc./Fujifilm Medical Systems USA, Inc./ Fujifilm Holdings America Corporation/Fujifilm
  • 3.6. GE Healthcare, Inc./General Electric Company
  • 3.7. Hitachi Aloka Medical America/Hitachi Aloka Medical/ Hitachi Medical/Hitachi
  • 3.8. Hologic, Inc.
  • 3.9. Mammotome/Devicor Medical Products, Inc.
  • 3.10. Mindray Medical USA Corporation/Mindray Medical International LTD
  • 3.11. Philips Healthcare, Inc./Royal Philips NV
  • 3.12. Qiagen NV
  • 3.13. Samsung Medison/Samsung Electronics America, Inc./ Samsung Electronics Co., LTD/Samsung
  • 3.14. Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG
  • 3.15. Toshiba America Medical Systems, Inc./Toshiba Corporation

APPENDIX: COMPANY LISTING

Back to Top